Anacor Pharmaceuticals Announces Favorable Ruling in Its Arbitration With Valeant Pharmaceuticals

Anacor Awarded $100 Million in Damages

Anacor Pharmaceuticals (ANAC) today announced that the arbitrator appointed to resolve its dispute with Valeant Pharmaceuticals, Inc. (Valeant), successor in interest to Dow Pharmaceutical Sciences, Inc. (DPS), has issued an Interim Final Award in favor of Anacor, awarding Anacor $100 million in damages as well as all costs of the arbitration and reasonable attorney’s fees.

The parties may apprise the arbitrator of any issues not resolved in the Interim Final Award order within ten days, and responses to any such submission are due within fifteen days of the date of the Interim Final Award. If no submissions are made, this Interim Final Award will become final

Published: 18 October 2013
Written by Editor
Nasdaq   High Tech   Project Updates   Up on News   Interesting News  
Read more: Anacor Pharmaceuticals ( ANAC )

Aratana Agrees to Acquire Vet Therapeutics, Inc.

Adds Biologics to its Pet Therapeutics Platform
Announces $19.75M Equity Financing and $5M Expansion of Existing Debt Facility
Aratana to Host Conference Call Monday, October 14 at 8:00 a.m. Eastern Time

 Aratana Therapeutics, Inc. (PETX), a biopharmaceutical company focused on the licensing, development and commercialization of innovative medications for pets (pet therapeutics), today announced that it has entered into a merger agreement providing for the strategic acquisition of Vet Therapeutics, Inc., a San Diego-based company with a proprietary antibody-based biologics platform.  Under the agreement, Aratana plans to continue to advance the pipeline of high value biologic drugs, including its lymphoma franchise.  Importantly, the acquisition of Vet Therapeutics is expected to significantly accelerate Aratana's pathway toward becoming a commercial-stage pet therapeutics company.

Published: 14 October 2013
Written by Editor
Nasdaq   Healthcare   M & A   Up on News   Interesting News  
Read more: Aratana Therapeutics Inc ( PETX )

Medicure Announces Approval of Recommended Dosing Regimen for AGGRASTAT(R)

FDA Approves Supplemental New Drug Application

Medicure Inc. ("Medicure" or the "Company") (TSX VENTURE:MPH)(MCUJF), is pleased to announce that the United States Food and Drug Administration (FDA) has approved the AGGRASTAT® (tirofiban HCl) high-dose bolus (HDB) regimen, as requested under Medicure's supplemental New Drug Application (sNDA). The AGGRASTAT HDB regimen (25 mcg/kg over 3 minutes, followed by 0.15 mcg/kg/min) now becomes the recommended dosing for the reduction of thrombotic cardiovascular events in patients with non-ST elevated acute coronary syndrome (NSTE-ACS).

Published: 11 October 2013
Written by Editor
TSX Venture   Healthcare   Project Updates   Up on News   Interesting News  
Read more: Medicure Inc ( MPH )

Cell Therapeutics Announces Agreement with the FDA on Special Protocol Assessment for Planned Pivotal Phase 3 Trial of Pacritinib in Myelofibrosis

- PERSIST-2 trial expected to initiate in fourth quarter of 2013 -

Cell Therapeutics, Inc. (CTI) (NASDAQ and MTA: CTIC) today announced that the company reached agreement with the U.S. Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for the planned pivotal Phase 3 clinical trial, known as the PERSIST-2 trial, evaluating pacritinib compared to best available therapy, including approved JAK2 inhibitors such as ruxolitinib, in patients with myelofibrosis whose platelet counts are

Published: 07 October 2013
Written by Editor
Nasdaq   Healthcare   Project Updates   Up on News   Interesting News  
Read more: Cell Therapeutics Inc ( CTIC )

GW Pharmaceuticals Announces New Sativex® Data at ECTRIMS

- New data reinforces the efficacy and safety profile of Sativex® in Multiple Sclerosis Spasticity -

GW Pharmaceuticals plc (AIM: GWP, Nasdaq: GWPH, "GW") announced that data from new MS spasticity studies (clinical trial data, observational study data and registries data collection) is being presented today at the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Copenhagen, Denmark. The following press release was issued today by GW's commercial partner, Almirall S.A., regarding the data presentation:

Published: 03 October 2013
Written by Editor
Nasdaq   Healthcare   Project Updates   Up on News   Interesting News  
Read more: GW Pharmaceuticals plc ( GWPH )
  1. Lexicon Pharmaceuticals Inc ( LXRX )
  2. GenVec Inc ( GNVC )
  3. Cyclacel Pharmaceuticals Inc ( CYCC )
  4. Regado Biosciences Inc ( RGDO )
  5. KYTHERA Biopharmaceuticals Inc ( KYTH )